CURRICULUM VITAE
`
`Robert R. Ruffolo, Jr., Ph.D., D.Sc. (honoris causa), D.Eng. (honoris causa), F.C.P.P.
`
`
`
`
`
`
`
`
`
`
`
`
`Telephone: 610-469-9308
`Fax: 610-469-8711
`
`Telephone: 484-467-4982
`Fax: 484-875-3101
`E-Mail Address: rruffolo@comcast.net
`
`Residence (Preferred Mailing Address)
`
`
`
`725 Pughtown Road
`Spring City, Pennsylvania 19475
`
`Office
`
`101 Lindenwood Drive, Suite 225
`Malvern, PA 19355
`
`
`
`
`
`
`
`
`Personal
`
`
`Born:
`Marital Status:
`Children:
`
`
`
`
`
`
`Education
`
`1968-1973 The Ohio State University
`
`
`
`
`
`
`
`1973-1976 The Ohio State University
`
`Professional Experience
`
`2008- Present
`
`2008-2009
`
`2002-2008
`
`April 14, 1950, Yonkers, New York
`Married, Stephany Ruffolo
`Michael Robert Ruffolo, Born October 4, 1983
`Brian John Ruffolo, Born February 7, 1989
`Jennifer Suzanne Ruffolo, Born June 18, 1991
`
`B.S., summa cum laude and
`with Distinction in Pharmacy.
`
`Ph.D. in Pharmacology
`
`President, Ruffolo Consulting, LLC (Pharmaceutical Consulting)
`
`Consultant, Wyeth Pharmaceuticals
`
`
`2002-2008
`
`2007-2008
`
`2007-2008
`
`2000-2002
`
`
`1998-2000
`
`President, Research and Development, Wyeth (Responsibility for
`approximately 9,000 staff, >$3 Billion Budget)
`
`Senior Vice President, Wyeth (Corporation)
`
`Director, Wyeth Pharmaceuticals Inc. (Domestic Entity)
`
`Director, Genetics Institute Europe, Inc.
`
`Executive Vice President, Research and Development, Wyeth Research
`(Responsibility for approximately 4500 staff, $1.6 Billion Budget)
`
`Senior Vice President and Director, Research Worldwide, SmithKline
`Beecham Pharmaceuticals (acting, while Head of Research recovered
`
`P.1
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`-2-
`
`
`
`from automobile accident) (Responsible for 1700 staff, $180 Million
`Budget) [Received a Special Commendation for performance]
`
`P.2
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`-3-
`
`
`
`Professional Experience (Continued)
`
`1998-2000 Senior Vice President and Director, Biological Sciences, Worldwide, SmithKline
`Beecham Pharmaceuticals (Responsibility for approximately 500 staff, $105
`Million Budget)
`
`
`1995-1998 Vice President and Director, Pharmacological Sciences, Worldwide,
`
`and Medicinal Chemistry, Europe, SmithKline Beecham Pharmaceuticals
`(Responsibility: >300 staff)
`
`
`1992-1995 Vice President and Director, Pharmacological Sciences, U.S., U.K.,
`
`Europe and Australia, SmithKline Beecham Pharmaceuticals
`
`(Responsibility: >300 staff)
`
`1990-1992 Vice President and Director, Pharmacological Sciences, U.S.,
`
`SmithKline Beecham Pharmaceuticals (Responsibility: 120 staff)
`
`1989-1990 Vice President, Pharmacological Sciences, Smith Kline & French
`
`Laboratories (Responsibility: 120 staff)
`
`1987-1989 Group Director, Department of Pharmacology and Department of
`
`Molecular Pharmacology, Smith Kline & French Laboratories
`
`(Responsibility: 140 staff)
`
`1985-1987 Director, Cardiovascular and Renal Pharmacology, Smith Kline &
`
`French Laboratories (Responsibility: 41 staff)
`
`1984-1985 Director, Cardiovascular Pharmacology, Smith Kline & French
`
`Laboratories (Responsibility: 24 staff)
`
`1983-1984 Chairman, Cardiovascular Research Committee, Lilly Research
`
`Laboratories
`
`1982-1984 Research Scientist, Lilly Research Laboratories, Department of
`
`Cardiovascular Pharmacology
`
`1981-1982 Senior Pharmacologist, Lilly Research Laboratories, Department of
`
`Cardiovascular Pharmacology
`
`1978-1981 Senior Pharmacologist, Lilly Research Laboratories, Department of Cell
`Biology
`
`
`1977-1978 Staff Fellow, Postdoctoral Research Associate, National Heart, Lung and
`Blood Institute, The National Institutes of Health, Laboratory of Biochemical
`Genetics (Chief, Dr. Marshall Nirenberg, Nobel Laureate)
`
`
`1976-1977 Postdoctoral Research Associate, The Ohio State University
`
`1973-1976 Graduate Fellow, The Ohio State University (Thesis Advisor,
`Dr. Popat N. Patil)
`
`
`
`P.3
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`-4-
`
`
`
`Resolution: Scroll of Appreciation, West Virginia University Foundation
`
`Chauncey D. Leake Award, The Ohio State University, Columbus, Ohio
`
`Honors, Awards and Recognitions
`
`2013
`
`2013
`
`2012
`
`Robert R. Ruffolo Career Achievement in Pharmacology Award (Medal)
`established by the American Society for Pharmacology and Experimental
`Therapeutics (ASPET)
`
` Elected, Fellow of The College of Physicians of Philadelphia (FCPP)
`
`Winner, Great Oxford Debate, Oxford, England
`
`Lifetime Achievement Award, The Ohio State University, Columbus, Ohio
`
`Target Leadership Lectureship, College of Pharmacy, University of Florida
`
`Scrip Lifetime Achievement Award, Scrip Annual Awards, London, UK
`
`“Best Pharmaceutical Company, R. Ruffolo, Scrip Awards, London, UK
`
`Legislative Commemoration, the State of South Dakota. Awarded for
`Discovery and Development of Coreg
`
`Tribute, Office of the Governor, State of Delaware. Awarded for Discovery
`and Development of Coreg
`
`Citation, Commonwealth of Pennsylvania, House of Representatives.
`Awarded for Discovery and Development of Coreg
`
`Resolution of Congratulations, Senate of the State of Pennsylvania.
`Awarded for Discovery and Development of Coreg
`
`Maurice Seevers Lectureship, Department of Pharmacology, Univ. Michigan
`
`William E. Hassan Distinguished Rho Chi Memorial Lecture, Massachusetts
`College of Pharmacy and Health Sciences
`
`Discoverer’s Award. Awarded for Coreg® (Carvedilol/Kredex) by PhRMA
`
`David Perlman Memorial Lectureship. American Chemical Society
`
`“Top Ten Pipeline: Strongest Women’s Health Pipeline”. Awarded to
`Robert R. Ruffolo by R&D Directions at the Drug Development Summit
`
`RADEX (R&D Executive Committee) Award for re-building Wyeth’s R&D
`
`Visionary Leadership Award, Wyeth Pharmaceuticals
`
`Pharmaceutical R&D Achievement Award, Accenture
`
`
`2011
`
`2009
`
`2009
`
`2009
`
`2008
`
`2008
`
`2008
`
`
`2008
`
`
`2008
`
`
`2008
`
`
`2008
`
`2008
`
`
`2008
`
`2008
`
`2008
`
`
`2008
`
`2008
`
`2008
`
`
`P.4
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`-5-
`
`
`
`Sino-American Pharmaceutical Professionals Special Service Award
`
`Professor of Physiology and Pharmacology. West Virginia University
`
`Honorary Doctorate in Engineering (D.Eng.). University of Catania, Italy
`
`Best Drug Development Pipeline. Awarded to R. Ruffolo for Wyeth Pipeline
`
`
`Honors, Awards and Recognitions (Continued)
`
`2008
`
`2007-2013
`
`2007 Honorary Doctorate of Science (D.Sc.). West Virginia University
`
`2007
`
`2007
`
`2007
`
`2007
`
`John S. O’Brien Memorial Lectureship. University of Pennsylvania
`
`138th Commencement Speaker, West Virginia University School of
`Medicine. West Virginia University, Morgantown, WV
`
`Profiled in The Star Ledger of New Jersey. Feature article entitled
`“Researcher Makes His Mark”, April 25, 2007.
`
`Profiled in Harvard Business Review. Wyeth Pharmaceuticals: Spurring
`Scientific Creativity with Metrics, February 2, 2007.
`
`“Top Ten Pipeline: Strongest CNS Pipeline”. Awarded to Robert R. Ruffolo
`by R&D Directions at the Drug Development Summit.
`
`Profiled in BusinessWeek Magazine. Feature article on re-engineering
`R&D, February 6, 2006.
`
`Centennial Award for Drug Discovery. Awarded for the discovery and
`development of Coreg® (Carvedilol) by Temple University.
`
`Listed as one of the “Most Notable Graduates” of The Ohio State University
`
`Research’s Shining Star. Designated by Med Ad News for Leading and Re-
`engineering Wyeth’s R&D
`
`Key To The City, Catania, Italy (awarded by Mayor)
`
`Designated as “Notable Alumni” by The Ohio State University.
`
`SAPA Special Award for Outstanding Contributions. Awarded by Sino-
`American Pharmaceutical Professionals Association (SAPA).
`
`Management Team of the Year. Awarded to R. Ruffolo by Scrip for his
`leadership of the Wyeth Research and Development Executive Committee
`
`Renowned Pharmaceutical Scientist. Named to list of top 200 Renowned
`Pharmaceutical Scientists by Pharmer.
`
`
`2007
`
`
`2007
`
`
`2007
`
`
`2006
`
`
`2006
`
`
`2006
`
`2006
`
`
`2006
`
`2006
`
`2006
`
`
`2006
`
`
`2006
`
`
`
`P.5
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`-6-
`
`
`
`Honors, Awards and Recognitions (Continued)
`
`2006
`
`“Top Ten Pipelines: The Strongest Primary Cure Pipeline”. Awarded to
`Robert R. Ruffolo by R&D Directions and Drug Discovery Summit.
`
`Profiled in Philadelphia Inquirer. Feature article entitled “Wyeth’s Front
`Man”, June 5, 2005.
`
`Designated as One of the 100 Most Inspiring People in the Life-Sciences
`Industry. Awarded by PharmaVOICE
`
`George B. Koelle Award for Scientific Excellence. Awarded by the Mid-
`Atlantic Pharmacology Society.
`2005 Executive of The Year Finalist. Scrip Awards.
`
`2005
`
`“Top Ten Pipelines: The Pipeline to Watch”. Awarded to Robert R. Ruffolo
`by R&D Directions and Drug Discovery Summit.
`
`SAPA-GP Excellence Award. Awarded by Sino-American Pharmaceutical
`Professionals Association
`
`Chief Scientific Officer of the Year. Awarded at the Third Annual
`Pharmaceutical Achievement Awards for exemplary innovation, scientific
`competence, leadership and organizational creativity in managing R&D.
`
`Corporate Recognition Award for Innovation by American Chemical Society
`
`Principal Corporate Officer, Senior Vice President, Wyeth (Corporation)
`
`Corporate Officer, Senior Vice President, Wyeth (Corporation)
`
`Designated ISI Highly Cited Researcher, in recognition of being in the top
`100 cited Pharmacologists worldwide over the past 20 years (1981-2001)
`
`
`2005
`
`
`2005
`
`
`2005
`
`
`2005
`
`
`2004
`
`
`2004
`
`2002-2008
`
`2002
`
`2002
`
`
`2002-2008
`
`Member, Pharmaceutical Research and Manufacturing Association
`(PhRMA) Foundation Board
`
`Member, BIO Board of Directors
`
`Member, Robert F. Furchgott Endowed Chair Committee
`
`Corporate Officer, American Home Products Corporation
`
`
`2003-2008
`
`2002-2008
`
`2001
`
`2001-Present Member, Pharmaceutical Research and Manufacturers Association
`(PhRMA), Science and Regulatory Executive Committee
`
`
`2000
`
`
`1999-2000
`
`SmithKline Beecham "Battlefield Award" for exceptional performance in
`SmithKline Beecham in litigation on Phentermine. Cash Award.
`
`Principle Actor; National television and print media campaign for the
`Pharmaceutical Research and Manufacturers of America. Selected for the
`discovery and development of Coreg (carvedilol) for congestive heart failure
`
`P.6
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`-7-
`
`
`
`
`Honors, Awards and Recognitions (Continued)
`
`1999
`
`
`1998
`
`1998
`
`
`1998
`
`
`1998
`
`
`1997
`
`
`1997
`
`1997
`
`
`1997
`
`
`1994-1997
`
`
`1996
`
`
`1996
`
`1995
`
`
`1995
`
`
`1995
`
`1994
`
`
`1991
`
`Lorenzini Gold Medal for Biomedical Research, Lorenzini Medical Science
`Foundation
`
`Member (elected), Mark Nickerson Lecture Award Endowment Committee
`
`Chairman, International Union of Pharmacology (IUPHAR) Committee on
`Receptor Classification and Nomenclature
`
`John V. Croker Lecturer, The American Society for Pharmacology and
`Experimental Therapeutics
`
`Special Commendation awarded by SmithKline Beecham's Corporate
`Management Team for supervising Worldwide Discovery while head of
`Discovery recuperated from a serious automobile accident. Cash award.
`
`Visiting Lecturer of the Hungarian Academy of Sciences (elected by HAS),
`Budapest, Hungary
`
`Albert Szentgyörgy Medal, Szentgyörgy Medical School, Szeged, Hungary
`
`U.S. Pharmaceutical President's Award in Recognition of Outstanding
`Contribution for Research on Carvedilol (Coreg), U.S. Pharmaceuticals
`Division, SmithKline Beecham Pharmaceuticals
`
`R&D President's Gold Impact Award in Recognition of Outstanding
`Contribution to Carvedilol (Coreg) Approval for Congestive Heart Failure,
`Research and Development, SmithKline Beecham Pharmaceuticals.
`
`Secretary/Treasurer, American Society for Pharmacology and Experimental
`Therapeutics (ASPET; Elected Position)
`
`Prix Galien Research Award Citation and Commendation for Innovation and
`Excellence in Research; Nonpeptide Endothelin Receptor Antagonists UK
`
`Prix Galien Innovation Research Award. United Kingdom
`
`Maloney-Booker Lecturer in Pharmacology. College of Medicine,
`Howard University, Washington, D.C.
`
`Distinguished Service Award, Publications Committee, Federation of
`American Societies for Experimental Biology
`
`Simply the Best Award, presented by CEO of SmithKline Beecham
`
`Distinguished Visiting Professor, Department of Pharmacological and
`Pharmaceutical Sciences, University of Houston, Houston, Texas
`
`Diploma - El Postgrado de Farmacologia, Universidad Central de
`Venezuela, Facultad de Farmacia, Caracas, Venezuela
`
`P.7
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`-8-
`
`
`
`Distinguished Alumni Award, The Ohio State University
`
`Honors, Awards and Recognitions (Continued)
`
`1989
`
`1989
`
`Certificate of Appreciation, Food and Drug Administration, Committee for
`Advanced Scientific Education
`
`John Jacob Abel Award in Pharmacology, American Society for
`Pharmacology and Experimental Therapeutics
`
`R&D President's Award, SmithKline Beckman Pharmaceuticals, for
`Exceptional Performance with CEO in presentation of R&D Pipeline to
`Analysts and Investors. Cash Award.
`
`Travel Award granted by the American Society for Pharmacology and
`Experimental Therapeutics to attend the Ninth IUPHAR International
`Congress for Pharmacology, London, England.
`
`Queen Beatrix Medal, Koningin Der Nederlanden, The Netherlands.
`
`Travel Award granted by the American Society for Pharmacology and
`Experimental Therapeutics to attend the Eighth IUPHAR International
`Congress for Pharmacology, Tokyo, Japan
`
`PRAT Fellow: Fellow of the National Institutes of General Medical
`Sciences. Pharmacology Research Associate Training Fellowship
`
`Phi Kappa Phi Honor Society, The Ohio State University
`
`Fellowship from the American Foundation for Pharmaceutical Education
`
`B.S. Summa cum laude, The Ohio State University
`
`Rho Pi Phi Scholastic Award, The Ohio State University
`
`George B. Kauffman Memorial Award for Scholarship, The Ohio State
`University
`
`Rho Chi Pharmaceutical Honor Society, The Ohio State University
`
`Rho Chi Scholarship Recognition Award, The Ohio State University
`
`Miami Valley Pharmaceutical Association Scholastic Award, The Ohio State
`University
`
`
`1988
`
`
`1988
`
`
`1984
`
`
`1982
`
`1981
`
`
`1977-1978
`
`
`1976
`
`1973-1976
`
`1973
`
`1973
`
`1973
`
`
`1972
`
`1972
`
`1972
`
`
`
`P.8
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`-9-
`
`
`
`Major Personal Role in the Discovery and Development of the Following Marketed Products
`
` 
`
` Dobutrex (Dobutamine) for Congestive Heart Failure
`
` Requip (Ropinerole) for Parkinson's Disease
`
` Teveten (Eprosartan) for Hypertension
`
` Coreg/Kredex (Carvedilol) for Congestive Heart Failure and Acute Myocardial Infarction
`
`
`
` 
`
`The Following Products Were Approved During Tenure as President of Research &
`Development, Wyeth Pharmaceuticals
`
` Effexor for Depression and multiple indications
`
` Enbrel for Rheumatoid Arthritis and other Indications
`
` Pristiq (Desvenlefaxine) for Depression
`
` Relistor (Methylnaltrexone) for Opiate-Induced Consitpation
`
`
`
`InFuse (rhBMP-2) for Bone Healing
`
` Torisel (Temsirilomus) for Renal Cancer
`
` Lybrel (Levo Ethynylestradiol) for Continuous Contraception
`
` Xyntha (rhFactor VIII) for Hemophilia
`
` Tygacil (Tygacycline) Broad Spectrum Injectable Antibiotic
`
` Mylotarg (Gemtuzumab Ozogamicin) for Acute Myelogenous Leukemia
`
` Premarin (Conjugated Estrogens), Low Dose
`
` PremPro (Conjugated Estrogens/Progestin), Low Dose
`
` DuaVee (Conjugated Estrogens/Bazedoxifene) for Menopausal Symptoms
`
` Prevnar and Prevnar 13 vaccines for Pneumococcal Disease (children and adult)
`
`P.9
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`-10-
`
`
`
`Philanthropic Activities
`
` 
`
` Established the Ruffolo Charitable Fund to support many charities, humanitarian projects
`and educational programs throughout the World
`
` With the American Society for Pharmacology and Experimental Therapeutics (ASPET),
`established the Robert R. Ruffolo Career Achievement in Pharmacology Award (Medal)
`in Pharmacology
`
` 
`
` 
`
` 
`
` Underwrote the renovation of the Robert & Stephany Ruffolo Lecture Hall in the College
`of Pharmacy at The Ohio State University
`
` Established the Robert & Stephany Ruffolo Endowed Scholarship at The Ohio State
`University College of Pharmacy
`
` Established the Popat N. Patil Endowed Scholarship at The Ohio State University College
`of Pharmacy in honor of his former Professor and Advisor
`
` 
`
` Established the Robert & Stephany Ruffolo Endowed Scholarship at The Ohio State
`University Fisher School of Business
`
` 
`
` Established the Robert & Stephany Ruffolo Endowed Scholarship at West Virginia
`
`University School of Pharmacy
`
` Established the Robert & Stephany Ruffolo Endowed Research Fellowship at West
`
`Virginia University School of Pharmacy
`
` Funded over 20 Non-Endowed Robert & Stephany Ruffolo Scholarships at West Virginia
`
`University College of Pharmacy
`
`
`
`P.10
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`-11-
`
`
`
`
`
`Philanthropic Activities (Continued)
`
` 
`
` Established the Robert & Stephany Ruffolo Endowed Research Fellowship at the
`
`University of Florida College of Medicine
`
` Major Donor to the Mali Health Organization Project
`
` Named “American Patriot” by Bill O’Reilly live “on air” on the Fox News Network and on
`the Bill O’Reilly website for his “Generous Donation to the Fisher House Foundation”
`which is dedicated to help fallen and disabled military and their families.
`
`P.11
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`-12-
`
`
`
`Ruffolo Consulting, LLC, Clients (Past and Present)
`
` Wyeth Pharmaceuticals
` Pfizer Pharmaceuticals
` Takeda Pharmaceuticals
` Merck, Sharp & Dohme
` EMD Serono Pharmaceuticals (Merck KGaA)
` Johnson & Johnson
` Novartis
` GlaxoSmithKline
` Teva Pharmaceuticals
` Shire Pharmaceuticals
` The Carlyle Group
` PPD (Pharmaceutical Product Development)
` Accenture
` McKinsey
` UCB
` Alcon
` Highfields Capital Management
` Tessella
` Trevena Pharmaceuticals
` Keddem Biotech
` Gillead
` HemoShear Technologies
` GLG Institute
` Gardner Roberts, LLP
` Goodwin-Proctor, LLP
`
`
`
`
`P.12
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`-13-
`
`
`
` Trevena Pharmaceuticals (Board of Directors and Scientific Advisory Board)
`
`
`
` 
`
`Board Memberships and Consultancies (Past and Present)
`
` West Virginia University Foundation (Board of Directors)
`
` Gene Network Sciences (Scientific Advisory Board)
`
` HemoShear Pharmaceuticals (Scientific Advisory Board)
`
` Ore Pharmaceuticals (Scientific Advisory Board)
`
` West Virginia University School of Pharmacy Dean’s Board of Directors
`
` University of Michigan Health Sciences Center
`
` The Ohio State University School of Business
`
` Mali Health Organization Project Board
`
` EMD Serono (International Advisory Board)
`
` DNDi (Drugs for Neglected Diseases Initiative) (Scientific Advisory Board)
`
` Sapience Pharmaceuticals (Board of Directors)
`
` Sigilon Pharmaceuticals (Board of Directors)
`
` Aridis Pharmaceuticals (Board of Directors)
`
`
`Expert Witness in Lawsuits
`
` 
`
` SmithKline Beecham Litigation on Diet Drug-induced Primary Pulmonary Hypertension
`
`and Valvular Heart Disease (1998-2000)
`
` Wyeth Pharmaceuticals Hormone Therapy Litigation following publication of the Women’s
`
`Health Initiative (2007)
`
` Patent Litigation, Gardner Roberts LLP (2009-2010)
`
` Patent Litigation; Goodwin-Procter LLP (2010-2013)
`
`P.13
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`-14-
`
`
`
`Academic Appointments
`
`Adjunct Professor of Physiology and Pharmacology, School of
`Medicine, West Virginia University
`
`Corporate Advisory Board for the University of Michigan Medical School
`
`Corporate Advisory Board, University of Pennsylvania School of
`Nursing
`
`Adjunct Professor, Division of Pharmacology, College of Pharmacy,
`The Ohio State University, Columbus, Ohio
`
`University of Pennsylvania School of Nursing Board of Overseers
`
`Ohio State University College of Pharmacy Dean’s Corporate Council
`
`West Virginia University School of Pharmacy Dean’s Advisory Board
`
`Adjunct Professor, Department of Pharmacology, School of
`Medicine, Baylor University, Houston, Texas
`
`Adjunct Professor, Department of Pharmacology, School of
`Medicine, McGill University, Montreal, Canada
`
`Board of Visitors, School of Pharmacy, University of Wisconsin,
`Madison, Wisconsin
`
`
`
`2007-2014
`
`
`2004-2008
`
`2004-2008
`
`
`1989-Present
`
`
`2004-2008
`
`2004-2009
`
`2000-2008
`
`1990-2001
`
`
`1982-1989
`
`
`1993-1996
`
`
`
`
`Professional Affiliations
`
`Coalition Against Major Diseases, The Brookings Institute (Chaired by Dr. Mark McClellan,
`
`Former Commissioner of the FDA and CMS)
`
`American Society for Pharmacology and Experimental Therapeutics (ASPET)
`
`British Pharmacological Society (BPS)
`
`International Union of Pharmacology (IUPHAR)
`
`Federation of American Societies of Experimental Biology (FASEB)
`
`Experimental Biology (EB)
`
`Society of Critical Care Medicine (SCCM)
`
`Mid-Atlantic Pharmacology Society (MAPS)
`
`P.14
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`-15-
`
`
`
`Screen Actors Guild (SAG); Principal Performer in Television Advertisement for
`
`Pharmaceutical Research and Manufacturers of America
`
`SAPA Board of Advisors
`
`Center for Biomedical Innovation; MIT
`
`Drugs for Neglected Diseases (DNDi)
`
`University of Florida College of Pharmacy Dean’s National Advisory Board
`
`
`
`
`
`
`
`Professional Affiliations (Continued)
`
`P.15
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`-16-
`
`
`
`Editorial Responsibilities
`
`Editor-in-Chief, Current Opinions in Pharmacology (2000-2008)
`
`Founding Editor, Current Opinions in Pharmacology (2000)
`
`Editor-in-Chief, Pharmacology Reviews and Communications (1996-2000)
`
`Founding Editor, Pharmacology Reviews and Communications (1996)
`
`Editor, British Journal of Pharmacology (1998-2000).
`
`Editor-in-Chief, Pharmacology Communications (1991-1996).
`
`Founding Editor, Pharmacology Communications (1991)
`
`Editor, Critical Reviews in Pharmacology (1993-1995)
`
`Editor, The Journal of Pharmacology and Experimental Therapeutics; Autonomic
`Pharmacology (1985-1992).
`
`Editor, Cardiovascular Drugs and Therapy; Adrenergic Modulation (1994-Present)
`
`Editor, Cardiovascular and Renal Drugs, Current Opinion in Investigational Drugs (1992-
`present).
`
`Co-Editor, Neuropharmacology, Textbook of Basic and Clinical Pharmacology (1990-1994)
`
`Guest Editor, Autonomic Pharmacology, The Journal of Pharmacology and Experimental
`Therapeutics, 1982-1985.
`
`
`
`P.16
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`-17-
`
`
`
`Editorial Advisory Boards
`
`British Journal of Pharmacology (1998 - 2000)
`The Journal of Pharmacology and Experimental Therapeutics (1981 - 1986)
`Journal of Cardiovascular Pharmacology (1991 - present)
`Cardiovascular Drugs and Therapy (1993 - present)
`Annual Reviews of Pharmacology (1991 - 1995)
`Journal of Autonomic Pharmacology (1984 - present)
`Fundamental and Clinical Pharmacology (1986 - 1992)
`Journal of Medicinal Chemistry (1989 - 1995)
`Trends in Pharmacological Sciences (1990 - present)
`The Spilker Report (2004 - present)
`Medicinal Research Reviews (1994 - 2003)
`FASEB Journal Publications Committee (1989 - 1995)
`Receptor (1989 - 1996)
`Drug Development Research (1995 - Present)
`Year Book of Pharmacology (1988 - 1992)
`Journal of Chirality (1988 - 1996)
`Drug News & Perspective (1989 - present)
`Pharmacology Communications (1991 - 1996)
`CRC Critical Reviews in Pharmacology (1992 - 1996)
`Investigational Drugs Database (1993 - present)
`Pharmaceutical News (1994 - present)
`Research Biochemicals International (1993 - 1997)
`Current Protocols in Pharmacology (1995 - 2001)
`Receptors and Signal Transduction (1995 - 1996)
`Pharmacology Reviews and Communications (1996 - Present)
`Current Opinions in Pharmacology (2000 - Present)
`Phacilitate: R&D Leaders Forum (2001 - Present)
`Expert Review on Drug Metabolism and Toxicology (2004 – Present)
`Expert Opinion on Drug Discovery (2005 – Present)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`P.17
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`-18-
`
`
`
`Reviewer for Research Grants
`
`National Institutes of Health, National Institute on Drug Abuse, Study Section: Drug Abuse
`Biomedical Research Review Committee, 1984, Special Review Consultant
`
`
`National Institutes of Health, Bio-organic and Natural Products Chemistry Study Section,
`1984, Special Review Consultant
`
`
`National Science Foundation, Molecular and Cellular Neurobiology Section 1984
`
`Medical Research Council of Canada, Montreal
`
`Tobacco and Health Institute, Lexington, Kentucky
`
`National Institutes of Health, Study Section, Cardiovascular Pharmacology; Special
`
`Review Consultant, 1986
`
`National Institutes of Health Study Section, Autonomic Pharmacology; Special Review
`Consultant, 1986
`
`
`National Institutes of Health Study Section, Receptor Pharmacology; Special Review
`Consultant, 1986
`
`
`National Institutes of Health, Study Section; Special Review Consultant, 1987
`
`Member, Site Visit Committee, National Heart, Lung and Blood Institute, Stanford University,
`1988
`
`
`Member, Site Visit Committee, National Heart, Lung and Blood Institute, University of
`Chicago, 1988
`
`
`
`P.18
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`-19-
`
`
`
`American (ASPET) and International (IUPHAR) Pharmacology Society Roles
`
`Council Member, Drug Discovery, Drug Development and Regulatory Affairs, Division of the
`American Society for Pharmacology and Experimental Therapeutics (1999-2008)
`
`
`Officer, IUPHAR 2002 World Congress, 1996-2002.
`
`Chairman, IUPHAR Committee for Receptor Nomenclature and Drug Classification
`
`(1998 - 2002)
`
`ASPET Sollmann Award Selection Committee (1997)
`
`Chairman, IUPHAR Finance Committee, International Union for Pharmacology
`
`(1995 - 2002)
`
`IUPHAR Subcommittee for Receptor Nomenclature and Drug Classification: Endothelin
`Receptors (1995 - 2002), International Union for Pharmacology (IUPHAR)
`
`
`ASPET Sollmann Award Selection Committee (1995)
`
`IUPHAR Committee for Receptor Nomenclature and Drug Classification (1994-present),
`International Union for Pharmacology
`
`
`Member, ASPET Council (1994-1997)
`
`Member, ASPET Finance Committee (1994-1997)
`
`Chairman, ASPET Finance Committee (1995-1996)
`
`Member, ASPET Investment Subcommittee (1995-1996)
`
`Secretary/Treasurer, American Society for Pharmacology and Experimental Therapeutics
`(1994-1997) (Elected Position)
`
`
`Committee on Industrial - Academic Relations, American Society for Pharmacology and
`
`Experimental Therapeutics (1993 - 1994)
`
`Nomination Committee, American Society For Pharmacology and Experimental
`
`Therapeutics (1992 - 1993) (Elected Position).
`
`Subcommittee on Pharmacology in Industry, (1990-1992), American Society for
`
`Pharmacology and Experimental Therapeutics (ASPET)
`
`IUPHAR Subcommittee for Receptor Nomenclature and Drug Classification:
`
`Adrenoceptors (1990-present), International Union for Pharmacology (IUPHAR).
`
`Publications Committee, the FASEB Journal (1989-present), Federation of American
`
`Societies for Experimental Biology (FASEB)
`
`
`P.19
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`-20-
`
`
`
`American (ASPET) and International (IUPHAR) Pharmacology Society Roles (continued)
`
`Selection Committee (1985), Pharmacology Research Associate Training (PRAT)
`
`Fellowships National Institute of General Medical Sciences, National Institutes
`
`of Health
`
`Program Committee (1984-1989), American Society for Pharmacology and Experimental
`
`Therapeutics
`
`
`P.20
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`-21-
`
`
`
`Invited Lectures
`
`University of Kansas, Department of Pharmacology, Lawrence, Kansas. Synapse turnover:
`A mechanism for acquiring synaptic specificity, 1978.
`
`
`Mayo Clinic, Department of Pharmacology, Rochester, Minnesota. Alpha-Adrenergic Activity
`of Clonidine-like Imidazolines, 1979.
`
`
`University of Connecticut, Department of Neurobiology, Storrs, Connecticut. Synapse
`Turnover: A Mechanism for Acquiring Synaptic Specificity, 1979.
`
`
`Northeastern University, Section of Pharmacology, College of Pharmacy,
`
`Boston, Massachusetts. Alpha-Adrenergic Effects of Imidazolines and -
`Phenethylamines, 1981.
`
`
`University of Kentucky, Department of Pharmacology, College of Medicine, Lexington,
`Kentucky. Peripheral and Central Effects of Adrenergic Agonists, 1981.
`
`
`Merck Institute for Therapeutic Research, Department of Cardiovascular Pharmacology,
`West Point, Pennsylvania. Evaluation of Clonidine-like Imidazolines from the
`Standpoint of Receptor Theory and Antihypertensive Activity, January 18, 1982.
`
`
`McGill University, Department of Pharmacology, College of Medicine, Montreal, Canada.
`Quantitative Analysis of Drug-Receptor Interactions in Classical Pharmacological
`Studies, March 2, 1982.
`
`
`McGill University, Department of Pharmacology, College of Medicine,
`
`Montreal, Canada. An Evaluation of the Antihypertensive Activity of Clonidine-Like
`Imidazolines From the Standpoint of Classical Receptor Theory, March 3, 1982.
`
`
`Dow Chemical Company, Department of Cardiovascular Pharmacology,
`
`Zionsville, Indiana. Central Alpha-Adrenergic Mechanisms in the Regulation of Blood
`Pressure. Evaluation From the Standpoint of Receptor Theory, May 3, 1982.
`
`
`Laboratoires D'Etudes et de Recherches SYNTHELABO, Department of Cardiovascular
`Pharmacology, Paris, France. Stereochemical Requirements of Alpha-2 Adrenergic
`Receptors, May 24, 1982.
`
`
`University of Amsterdam, Department of Pharmacodynamics, Amsterdam, The 1982.
`Differences Between the Interactions of Imidazolines and Phenethylamines with
`Alpha-Adrenergic Receptors, October 25, 1982.
`
`
`Emory University, Department of Pharmacology, Atlanta, Georgia.
`
`Peripheral and Central Effects of -Adrenergic Agonists, November 5, 1982.
`
`Emory University, Department of Pharmacology, Atlanta, Georgia. The Current Status of -
`Adrenergic Receptors. November 5, 1982.
`
`P.21
`
`UT Ex. 2023
`SteadyMed v. United Therapeutics
`IPR2016-00006
`
`

`
`-22-
`
`
`
`Invited Lectures (Continued)
`
`Smith Kline & French Laboratories, Department of Pharmacology, Philadelphia,
`Pennsylvania. Stereochemical requirements of 1and 2-adrenoceptors. July, 1982.
`
`State University of New York at Buffalo, Department of Biochemical Pharmacology, Buffalo,
`New York. Role of Central and Peripheral -Adrenergic Receptors in the Regulation
`of Blood Pressure. December 1, 1982.
`
`
`The Ohio State University, Division of Pharmacology, College of Pharmacy,
`
`Columbus, Ohio. The Role of Central and Peripheral -Adrenergic Receptors in the
`Regulation of Blood Pressure. February 9, 1983.
`
`
`Tulane University, Department of Pharmacology, School of Medicine, New Orleans,
`Louisiana. The Role of Central and Peripheral -Adrenoceptors in the Regulation of
`Blood Pressure. May 24, 1983.
`
`
`University of Mainz, Institute of Pharmacology, School of Medicine, Mainz, West Germany.
`The Role of Central and Peripheral -Adrenoceptors in the Regulation of Blood
`Pressure. June 21, 1983.
`
`
`University of Wurzburg, Department of Pharmacology, School of Medicine, Wurzburg, West
`Germany. The Role of Central and Peripheral -Adrenoceptors in the Regulation of
`Blood Pressure. June 22, 1983.
`
`
`Doctor's Hospital, Section on Critical Care Medicine, Grand Rounds, Columbus, Ohio.
`Central and Peripheral Regulation of the Cardiovascular System. September 7, 1983.
`
`
`Mayo Clinic, Department of Physiology and Biophysics, Rochester, Minnesota. The Role of
`Central and Peripheral -Adrenoceptors in the Regulation of Blood Pressure.
`December 19, 1983.
`
`
`Sloan-Kettering Memorial Hospital, Department of Critical Care Medicine, Grand Rounds,
`New York. Drug, Neurotransmitter and Hormone Receptors in the Regulation of the
`Cardiovascular System. December 16, 1983.
`
`
`Cook County Hospital, Department of Critical Care Medicine, Grand Rounds, Chicago.
`Central and Peripheral Regulation of the Cardiovascular System. May 10, 1984.
`
`
`University o